Solid tumors

Mechanism of action / Target

PMC-309 is an engineered monoclonal antibody that targets the negative immune checkpoint human VISTA (V-domain Ig suppressor of T cell activation). It indirectly promotes T cells' immune responses by inhibiting VISTA-expressing immunosuppressive cells, such as MDSCs (Myeloid-Derived Suppressor Cells) and M1 macrophages, and Tregs that  suppress T cell activation and proliferation.


The molecule's mechanism and preclinical efficacies have been confirmed in both in vitro and in vivo models. PharmAbcine initiated the GLP-tox study of PMC-309 in 2Q21 and expects an IND filing in 2Q22.


* The updated preclinical data of PMC-309 presented at AACR 2022

* The additional preclinical data of PMC-309 presented at KSMO 2021

* The preclinical data presentation at AACR 2021

     2F, Research Building 2, 70,

     Yuseong-daero 1689 beon-gil,
     Yuseong-gu, Daejeon, 34047, Republic of Korea

     HQ +82-42-863-2017 

     R&D Center +82-42-861-2017

     Investor Relations +70-4294-6097 

     FAX +82-42-863-2080 

     COPYRIGHT BY PharmAbcine Inc.